Hypothesis

Tumor‑derived exosomes enriched in succinate reprogram cancer‑associated fibroblasts (CAFs) to secrete MMP9, thereby remodeling the extracellular matrix, limiting drug penetration and fostering an immunosuppressive niche that drives acquired resistance to HER2‑targeted therapy.

Mechanistic Rationale

• Succinate, an oncometabolite, accumulates in the hypoxic tumor microenvironment and is packaged into exosomes via a mechanism linked to mitochondrial efflux ([1]).
• CAFs express the succinate receptor GPR91; ligand binding stabilizes HIF1α even under normoxia, transcriptionally upregulating MMP9 and TGF‑β1.
• Elevated MMP9 degrades collagen IV and laminin, exposing cryptic ECM fragments that bind CXCR4 on tumor cells, enhancing survival signaling and creating physical barriers that impede trastuzumab penetration.
• Simultaneously, TGF‑β1 skews tumor‑associated macrophages toward an M2 phenotype, suppressing CD8+ T‑cell infiltration—a process documented in metastatic gastric models ([2]).

This proteometabolomic axis explains why genomic profiling alone fails to predict resistance: the driver is a secreted metabolite‑protein circuit, not a mutational event.

Testable Predictions

1. Patients whose baseline plasma exosomes show high succinate‑to‑creatinine ratios will exhibit shorter progression‑free survival on HER2‑targeted regimens.
2. Longitudinal sampling will reveal a rise in exosomal succinate concurrent with increased CAF‑derived MMP9 peptide signatures before radiographic progression.
3. Pharmacologic inhibition of GPR91 (or neutralizing succinate with extracellular scavengers) in patient‑derived xenografts will reduce CAF MMP9 secretion, improve trastuzumab uptake, and restore tumor‑immune infiltration.
4. An attention‑based multi‑omics model that weights exosomal succinate and CAF MMP9 peptides above somatic HER2 copy number will predict resistance with >80% accuracy, outperforming a genomics‑only classifier.

Experimental Design

• Cohort: 60 HER2+ gastric adenocarcinoma patients receiving first‑line trastuzumab‑chemotherapy; collect plasma at baseline, every 4 weeks, and at progression.
• Assays: exosome isolation (ultracentrifugation or SEC), LC‑MS metabolomics for succinate, targeted proteomics (SRM) for MMP9, TGF‑β1, and CAF markers (α‑SMA, FAP).
• Endpoints: PFS, correlation of succinate/MMP9 dynamics with imaging (RECIST) and circulating tumor DNA.
• Validation: Orthotopic PDX models treated with trastuzumab ± GPR91 antagonist; measure exosomal succinate, fibroblast MMP9 (ELISA), tumor drug penetration (mass spec imaging), and flow cytometry for CD8+ T cells.

Potential Pitfalls

• Exosome heterogeneity may dilute succinate signal; mitigation via immuno‑affinity capture of HER2+ exosomes.
• Circulating MMP9 can originate from neutrophils; parallel neutrophil‑specific markers (MPO) will be used to deconvolute sources.
• Adaptive rewiring may bypass GPR91; serial multi‑omics will detect alternative resistance routes for iterative model updating.

If these predictions hold, the succinate‑MMP9 axis becomes a actionable, metaboloproteomic biomarker and therapeutic target, addressing the validation gap highlighted in current multi‑omics oncology efforts ([1]).